复方斑蝥胶囊对原发性肝癌患者免疫功能及临床疗效的影响

目的探讨复方斑蝥胶囊对原发性肝癌患者临床疗效及免疫功能的影响。方法选取2017年3月—2019年3月住院治疗的中晚期原发性肝癌患者共100例,按随机数字表法分为对照组与治疗组,每组各50例。对照组给予肝动脉插管栓塞化疗(Transcatheter arterial chemoembolization,TACE)治疗,治疗组在对照组治疗基础上给予复方斑蝥胶囊治疗。观察两组患者治疗前后临床效果、肿瘤标志物甲胎蛋白(A-fetoprotein,AFP)、癌胚抗原(Carcino-embryonic antigen,CEA)、糖抗原199(carbohydrate antigen 199,CA199)含量,免疫细胞因子血管内皮生长因子(vascular endothelial growth factor,VEGF)和缺氧诱导因子-1α(hypoxia inducible factor-1α,HIF-1α)水平及生活质量变化。结果治疗后,对照组总有效率为76%;治疗组总有效率为84%。治疗组总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗后对照组患者AFP、CA199含量降低,与治疗前比较,差异有统计学意义(P<0.05),CEA值虽有降低,但差异无统计学意义(P>0.05);治疗后治疗组患者血清中AFP、CEA、CA199含量显著降低,与治疗前比较,差异有统计学意义(P<0.05);且治疗组患者治疗后AFP、CEA、CA199含量降低程度优于对照组,差异有统计学意义(P<0.05)。两组患者治疗后血清中VEGF、HIF-1α含量均明显降低,与治疗前比较,差异有统计学意义(P<0.05);且治疗组患者血清中VEGF、HIF-1α含量降低优于对照组,差异有统计学意义(P<0.05)。治疗后治疗组KPS评分升高患者24例(48%),ZPS评分升高患者25例(50%),与对照组比较差异有统计学意义(P<0.05)。结论复方斑蝥胶囊联合TACE能显著提高原发性肝癌患者的临床效果,抑制肿瘤细胞的增殖,提高生存率,改善生活质量。

Effect of compound cantharidin capsules on clinical efficacy and immune function in patients with primary liver cancer

Objective To investigate the effect of compound cantharidin capsules on clinical efficacy and immune function in patients with primary liver cancer.Methods A total of 100 patients with advanced primary liver cancer hospitalized in our hospital from March,2017 to March,2019 were included and randomly divided into the control group(n=50)and the treatment group(n=50).The control group was treated with transcatheter arterial chemoembolization(TACE),and the observation group was treated with compound cantharidin capsules combined with TACE.The clinical effect,tumor markers A-fetoprotein(AFP),carcino-embryonic antigen(CEA),carbohydrate antigen 199(CA199),immune cell factors vascular endothelial growth factor(VEGF),hypoxia inducible factor-1α(HIF-1α)level and quality of life were observed before and after treatment.Results The total effective rate was 84%in the treatment group,which was significantly higher than that(76%)in the control group,with statistical significance(P<0.05).In the control group,AFT and CA199 decreased significantly,with statistical significance(P<0.05),and CEF decreased without significance(P>0.05).In the treatment group,serum levels of AFT,CEA and CA199 decreased compared with those before treatment,with statistical significance(P<0.05).The treatment group had larger reductions in AFP,CEA and CA199 than the control group,with statistical significance(P<0.05).VEGF and HIF-1αlevels decreased,compared with those before treatment,with statistical significance(P<0.05),and the treatment group had lower levels than the control group,with statistical significance(P<0.05).In the treatment group,24 patients(48%)had an increase in KPS score and 25 patients(50%)had an increase in ZPS score after treatment,and there was significant difference between the treatment group and the control group(P<0.05).Conclusion Compound cantharia capsules combined with TACE can significantly improve the clinical effect of patients with primary liver cancer,inhibit the proliferation of tumor cells,improve survival rate and the quality of life.